Business
Ocugen to Present at April 2026 Investor and Industry Conferences
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at O
About this update from Ocugen, Inc.
[{"type":"image","alt":"Ocugen","displaySize":"","headline":null,"caption":"Ocugen","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":171,"url":"https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Skm9e_O_sayLZV9VbrxBBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOQ--/https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a","width":300,"height":171}},"lazy":false},{"type":"text","content":"MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy.","length":620,"tagName":"p"},{"type":"text","content":"“I look forward to sharing our story with new audiences and building enthusiasm for why now is the time to get to know Ocugen,” said Dr. Musunuri. “Our gene-agnostic approach to addressing all mutations related to major blindness diseases has the potential to be first-in-class—disrupting existing treatment paradigms and bringing gene therapy to the masses. With our planned BLA submission for OCU400 beginning later this year, commercialization is within reach.”","length":464,"tagName":"p"},{"type":"text","content":"Innovation on the Island will include panels, company presentations, and networking opportunities. Biotech investors based in Puerto Rico as well as the continental United States will be in attendance.","length":201,"tagName":"p"},{"type":"text","content":"The Cell & Gene Meeting on the Med brings together the ATMP community from Europe and beyond and covers a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing. Ocugen is a proud member and collaborator with the meeting’s organizer, the Alliance for Regenerative Medicine.","length":333,"tagName":"p"},{"type":"text","content":"Details on the Company presentat...